At Arthritis4Cure, we believe autoimmune diseases should be treated at their biological origin - not managed indefinitely through chronic immunosuppression. 

Our therapeutic approach targets the pathogenic B cell clones sustaining autoimmune inflammation in rheumatoid arthritis. 

In ACPA-positive RA, autoreactive B cells fuel a vicious cycle of antibody production, inflammation, immune complex formation, and tissue destruction. 

Existing therapies may temporarily suppress inflammation but rarely interrupt the underlying disease-driving mechanisms. 

A4C-001 is a proprietary peptibody designed to disrupt this pathogenic loop selectively targeting disease-driving B cells while preserving broader immune function. 

Our goal is to refine treatment expectations for patients living with autoimmune diseases.